Nab-paclitaxel in combination with pyrotinib
Phase 2UNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 31/100
31
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Early Breast Cancer
Conditions
Early Breast Cancer
Trial Timeline
Jan 1, 2021 → Jun 1, 2025
NCT ID
NCT04659499About Nab-paclitaxel in combination with pyrotinib
Nab-paclitaxel in combination with pyrotinib is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Early Breast Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT04659499. Target conditions include Early Breast Cancer.
What happened to similar drugs?
2 of 20 similar drugs in Early Breast Cancer were approved
Approved (2) Terminated (2) Active (17)
❌PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxelBioconPhase 3
🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
🔄SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04659499 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Early Breast Cancer